Shire blueprints regenerative med expansion with new San Diego campus

When Shire ($SHPGY) bought out Advanced BioHealing in San Diego last year for $750 million, it trumpeted the addition of a new unit focused specially on regenerative medicine. And today it followed up with a blueprint to increase its footprint in that branch of biotech with a corporate campus in the Southern California biotech hub and plans to hire hundreds of new workers.

To better position itself for growth, Shire says it will build a 150,000-square-foot facility, Phase I in an expansion plan designed in anticipation of a swelling market for Dermagraft--a skin substitute--as well as adding new regenerative med products to the mix. Construction is slated to get under way in Sorrento Mesa next year with occupancy slated for 2014.

"This new campus will give us the flexibility and increased capacity we need to develop and manufacture new regenerative medicine therapies and build our foundation for continued growth in this exciting field," said Kevin Rakin, Shire's regenerative medicine president.

- here's the press release

Special Report: The biggest R&D spenders in biotech
 

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.